JP2007505094A - リターゲティングされる毒素結合体の設計 - Google Patents

リターゲティングされる毒素結合体の設計 Download PDF

Info

Publication number
JP2007505094A
JP2007505094A JP2006525899A JP2006525899A JP2007505094A JP 2007505094 A JP2007505094 A JP 2007505094A JP 2006525899 A JP2006525899 A JP 2006525899A JP 2006525899 A JP2006525899 A JP 2006525899A JP 2007505094 A JP2007505094 A JP 2007505094A
Authority
JP
Japan
Prior art keywords
target cell
agonist
cell
protease
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006525899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007505094A5 (https=
Inventor
フォスター，ケイス
チャドック，ジョン
ペン，チャールズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Public Health England
Original Assignee
Health Protection Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Protection Agency filed Critical Health Protection Agency
Publication of JP2007505094A publication Critical patent/JP2007505094A/ja
Publication of JP2007505094A5 publication Critical patent/JP2007505094A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2006525899A 2003-09-11 2004-09-13 リターゲティングされる毒素結合体の設計 Pending JP2007505094A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0321344.4A GB0321344D0 (en) 2003-09-11 2003-09-11 Re-targeted toxin conjugates
PCT/GB2004/003904 WO2005023309A2 (en) 2003-09-11 2004-09-13 Design of re-targeted toxin conjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012026892A Division JP6122243B2 (ja) 2003-09-11 2012-02-10 リターゲティングされる毒素結合体の設計

Publications (2)

Publication Number Publication Date
JP2007505094A true JP2007505094A (ja) 2007-03-08
JP2007505094A5 JP2007505094A5 (https=) 2009-11-26

Family

ID=29226936

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006525899A Pending JP2007505094A (ja) 2003-09-11 2004-09-13 リターゲティングされる毒素結合体の設計
JP2012026892A Expired - Lifetime JP6122243B2 (ja) 2003-09-11 2012-02-10 リターゲティングされる毒素結合体の設計

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012026892A Expired - Lifetime JP6122243B2 (ja) 2003-09-11 2012-02-10 リターゲティングされる毒素結合体の設計

Country Status (7)

Country Link
US (4) US20070184048A1 (https=)
EP (1) EP1667725A2 (https=)
JP (2) JP2007505094A (https=)
AU (1) AU2004269979B2 (https=)
CA (1) CA2538619C (https=)
GB (1) GB0321344D0 (https=)
WO (1) WO2005023309A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012508589A (ja) * 2008-11-17 2012-04-12 シンタキシン リミテッド 癌の抑制
JP2014516526A (ja) * 2011-05-16 2014-07-17 シンタクシン リミテッド 治療用融合タンパク質
US9416396B2 (en) 2008-02-20 2016-08-16 The Secretary Of State For Health Covalently linked thermostable kinase for decontamination process validation
US10466245B2 (en) 2008-02-20 2019-11-05 The Secretary Of State For Health Covalently linked thermostable kinase for decontamination process validation

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
HK1046020B (en) 1999-08-25 2007-05-11 Allergan, Inc. Activatable recombinant neurotoxins
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
EP1982997B1 (en) 2004-09-01 2012-08-08 Allergan, Inc. Degradable clostridial toxins
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US7659092B2 (en) 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
PL1830872T3 (pl) 2004-12-01 2011-09-30 Sec Dep For Health Białka fuzyjne
PL1877073T3 (pl) * 2004-12-01 2014-03-31 The Sec Dep For Health Niecytotoksyczne koniugaty białkowe
US8399400B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8021859B2 (en) 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
EP1871789B1 (en) 2005-03-15 2013-11-06 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
ES2369558T3 (es) 2005-09-19 2011-12-01 Allergan, Inc. Toxinas clostridiales y toxinas clostridiales activables.
GB0610868D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
AU2007272515B2 (en) 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
EP2505592A1 (en) 2006-07-11 2012-10-03 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
WO2009020748A2 (en) * 2007-07-16 2009-02-12 Avaxia Biologics, Inc. Antibody therapy for modulating function of intestinal receptors
EP2725035A1 (en) 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
EP2211890A1 (en) * 2007-10-23 2010-08-04 Allergan, Inc. Methods of treating urogenital-neurological disorders using modified clostridial toxins
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
JP5799397B2 (ja) 2008-06-12 2015-10-28 イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ 癌の抑制
GB0903006D0 (en) 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
ES2770033T3 (es) 2009-03-13 2020-06-30 Allergan Inc Ensayos de actividad de endopeptidasa redirigida basados en inmunología
KR20120061053A (ko) * 2009-08-27 2012-06-12 시냅틱 리서치, 엘엘씨 유도 만능 줄기(ｉＰＳ) 세포 또는 조직 특이적 세포를 생성하기 위한 신규한 단백질 전달 시스템
KR20120107988A (ko) 2009-12-16 2012-10-04 알러간, 인코포레이티드 통합된 프로테아제 절단 부위 결합 도메인을 포함하는 변형 클로스트리듐 독소
SI2684890T1 (sl) 2010-01-25 2016-10-28 Allergan, Inc. Metode znotrajcelične pretvorbe enoverižnih beljakovin v njihovo dvoverižno obliko
RU2561465C2 (ru) 2010-05-20 2015-08-27 Аллерган, Инк. Разрушаемые клостридиальные токсины
US20130330369A1 (en) 2010-10-08 2013-12-12 Allergan, Inc. Reduction Of Antibody Response Against Botulinum Neurotoxin And Variants Thereof
US20140056870A1 (en) * 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
GB201219024D0 (en) * 2012-10-23 2012-12-05 Syntaxin Ltd Assay
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TW201814045A (zh) 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 製造雙鏈梭狀芽孢桿菌神經毒素之方法
WO2018060351A1 (en) 2016-09-29 2018-04-05 Ipsen Biopharm Limited Hybrid neurotoxins
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09500867A (ja) * 1993-03-19 1997-01-28 ザ スペイウッド ラボラトリー リミテッド 細胞活性を制御するための新規作用薬
JPH11504006A (ja) * 1995-04-21 1999-04-06 ザ スペイウッド ラボラトリー リミッテッド 末梢感覚求心性機能を修正させ得るボツリヌス毒素誘導体
JP2002523377A (ja) * 1998-08-25 2002-07-30 マイクロバイオロジカル リサーチ オーソリティ 粘液過剰分泌の治療のための組換えボツリヌス菌毒素

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
DK1084146T3 (da) * 1998-05-13 2003-02-03 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Hybridprotein til inhibering af degranuleringen af mastocyter og anvendelse deraf
US6822076B2 (en) * 1998-05-13 2004-11-23 Biotecon Therapeutics Gmbh Hybrid protein for inhibiting the degranulation of mastocytes and the use thereof
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
EP2351838A1 (en) * 2000-10-20 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Crosslinking agonistic antibodies
EP1327681A4 (en) * 2000-10-20 2004-09-01 Chugai Pharmaceutical Co Ltd Degraded agonist antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09500867A (ja) * 1993-03-19 1997-01-28 ザ スペイウッド ラボラトリー リミテッド 細胞活性を制御するための新規作用薬
JPH11504006A (ja) * 1995-04-21 1999-04-06 ザ スペイウッド ラボラトリー リミッテッド 末梢感覚求心性機能を修正させ得るボツリヌス毒素誘導体
JP2002523377A (ja) * 1998-08-25 2002-07-30 マイクロバイオロジカル リサーチ オーソリティ 粘液過剰分泌の治療のための組換えボツリヌス菌毒素

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AGENTS AND ACTIONS, vol. 23, JPN6012023344, 1988, pages 16 - 17, ISSN: 0002217338 *
耳鼻咽喉科展望, vol. 38, JPN6012023347, 1995, pages 296 - 303, ISSN: 0002217339 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9416396B2 (en) 2008-02-20 2016-08-16 The Secretary Of State For Health Covalently linked thermostable kinase for decontamination process validation
US10466245B2 (en) 2008-02-20 2019-11-05 The Secretary Of State For Health Covalently linked thermostable kinase for decontamination process validation
JP2012508589A (ja) * 2008-11-17 2012-04-12 シンタキシン リミテッド 癌の抑制
JP2016005473A (ja) * 2008-11-17 2016-01-14 イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ 癌の抑制
US10113159B2 (en) 2008-11-17 2018-10-30 Ipsen Bioinnovation Limited Suppression of cancer
JP2014516526A (ja) * 2011-05-16 2014-07-17 シンタクシン リミテッド 治療用融合タンパク質

Also Published As

Publication number Publication date
WO2005023309A2 (en) 2005-03-17
GB0321344D0 (en) 2003-10-15
JP6122243B2 (ja) 2017-04-26
JP2012139222A (ja) 2012-07-26
AU2004269979B2 (en) 2009-12-10
US20070184048A1 (en) 2007-08-09
AU2004269979A1 (en) 2005-03-17
CA2538619C (en) 2012-10-16
WO2005023309A3 (en) 2005-09-15
CA2538619A1 (en) 2005-03-17
US20180362951A1 (en) 2018-12-20
EP1667725A2 (en) 2006-06-14
US20130122526A1 (en) 2013-05-16
US20090291457A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
JP6122243B2 (ja) リターゲティングされる毒素結合体の設計
JP6027035B2 (ja) 非細胞傷害性タンパク質結合体
ES2386838T3 (es) Inhibición de la secreción a partir de células no neuronales
US8852603B2 (en) Inhibition of secretion from non-neuronal cells
US20080152667A1 (en) Methods and compounds for the treatment of mucus hypersecretion
US10316061B2 (en) Synthesis of cell penetrating peptides for drug delivery and stem cell applications
US8603779B2 (en) Non-cytotoxic protein conjugates
US8470314B2 (en) Modified toxins
US10619146B2 (en) Non-cytotoxic protein conjugates
US8512984B2 (en) Non-cytotoxic protein conjugates
CN104769108A (zh) 用于治疗、预防或缓解疼痛的融合蛋白和方法
TW201819403A (zh) 雜合神經毒素
WO2007138336A2 (en) Treatment of pain by single chain, polypeptide fusion protein
US20080249019A1 (en) Treatment of mucus hypersecretion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070912

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091006

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20101203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110216

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110223

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110308

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110325

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110608

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120210

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120305

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130904

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130909